<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267746</url>
  </required_header>
  <id_info>
    <org_study_id>WAT 14-1096</org_study_id>
    <nct_id>NCT02267746</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, Inc.) in Treatment of Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and therapeutic equivalence of a generic
      tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the
      treatment of acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although topical retinoids have been individually used to successfully treat acne vulgaris,
      Fabior™ (Tazarotene) Foam, 0.1% is a safe and effective topical therapy used for the
      treatment of acne vulgaris. Actavis has developed a generic formulation of Tazarotene Foam,
      0.1%, and the current study is designed to evaluate the safety and efficacy of this
      formulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts</measure>
    <time_frame>Mean percent change from baseline to Week 12</time_frame>
    <description>For the purposes of study treatment and evaluation, these lesions were limited to the facial treatment area excluding the eyes, the lips, and angles of the nose (i.e., the lines around the nostrils and under the nostrils) and all mucus membranes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts</measure>
    <time_frame>Mean percent change from baseline to Week 12</time_frame>
    <description>Estimates of mean percent change from baseline for non-inflammatory lesions for the Test and Reference treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects With an IGA Score That is at Least 2 Grades Less Than the Baseline Assessment</measure>
    <time_frame>IGA score at Week 12 compared to baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">893</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Fabior™(tazarotene)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference listed drug: Fabior™ 0.1% foam (Stiefel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tazarotene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tazarotene 0/1% foam (Actavis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Foam vehicle of the test product (Actavis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene (Fabior™)</intervention_name>
    <arm_group_label>Fabior™(tazarotene)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene (Actavis)</intervention_name>
    <arm_group_label>Tazarotene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle foam</intervention_name>
    <arm_group_label>Vehicle foam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male or nonpregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of
        acne vulgaris.

        Informed Consent/Assent: Subjects ages 12 to 17 years inclusive must have provided IRB
        approved written assent; this written assent must be accompanied by an IRB approved written
        informed consent from the Subject's legally acceptable representative (i.e., parent or
        guardian). In addition, all Subjects or their legally acceptable representatives (i.e.,
        parent or guardian) must sign a HIPAA authorization.

        Subjects must have a minimum ≥ 30 non-inflammatory lesions (i.e., open and closed
        comedones) AND ≥ 25 inflammatory lesions (i.e., papules and pustules) AND no cystic lesions
        and only up to 1 facial nodular lesion (less than or equal to 5 mm) on the face. For the
        purposes of study treatment and evaluation, these lesions should be limited to the facial
        treatment area excluding the eyes, the lips, and angles of the nose (i.e. the lines around
        the nostrils and under the nostrils) and all mucus membranes. Subjects may have acne
        lesions on other areas of the body which will also be excluded from the count, treatment,
        and the Investigator's Global Assessment (IGA) evaluation (e.g., on the back, chest and
        arms).

        Subjects must have a severity grade 3, or 4 as per the Investigator's Global Assessment
        (IGA) (Section 6.2).

        Subjects must be willing to refrain from using all other topical acne medications or
        antibiotics during the 12-week treatment period for acne vulgaris, other than the
        Investigational Product.

        Female Subjects of childbearing potential (excluding women who are surgically sterilized or
        postmenopausal for at least 1 year), must have a negative urine pregnancy test (with
        sensitivity down to at least 50mIU/ml hCG) within 2 weeks prior to baseline.

        Female Subjects of childbearing potential (excluding women who are surgically sterilized or
        postmenopausal for at least 1 year), must be willing to use an acceptable form of birth
        control from the day of the first dose administration.. For the purpose of this study the
        following are considered acceptable methods of birth control: oral or injectable
        contraceptives, contraceptive patches, Depo-Provera® (stabilized for at least 3 months);
        NuvaRing® (vaginal contraceptive); Implanon™ (contraceptive implant) double barrier methods
        (e.g. condom and spermicide); IUD, or abstinence with a 2nd acceptable method of birth
        control should the Subject become sexually active. A sterile sexual partner is NOT
        considered an adequate form of birth control.

        All male Subjects must agree to use accepted methods of birth control with their partners,
        from the day of the first dose administration. Abstinence is an acceptable method of birth
        control for males.

        Subjects must be willing and able to understand and comply with the requirements of the
        protocol, including attendance at the required study visits.

        Subjects who use make-up must have used the same brands/types of make-up for a minimum
        period of 14 days prior to study entry and must agree to not change make-up brand/type or
        frequency of use throughout the study.

        -

        Exclusion Criteria:

        Female Subjects who are pregnant, nursing or planning to become pregnant during study
        participation.

        Subjects with a history of hypersensitivity or allergy to tazarotene and its excipients,
        and/or any of the study medication ingredients.

        Subjects with the presence of any skin condition that would interfere with the diagnosis or
        assessment of acne vulgaris. Such conditions include, but are not limited to the following:
        auto immune disease, rosacea; seborrheic dermatitis; perioral dermatitis;
        corticosteroid-induced acne; carcinoid syndrome; mastocytosis; acneform eruptions caused by
        make-up, medication, facial psoriasis and facial eczema, squamous cell carcinoma, steroid
        folliculitis, or bacterial folliculitis).

        Subjects who have acne congoblata, acne fulminans, and secondary acne (e.g., chloracne and
        drug induced acne) will be excluded from participation.

        Subjects with excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would
        interfere with diagnosis or assessment of acne vulgaris.

        Subjects who have used any of the following within 6 months prior to baseline or use during
        the study:

          1. oral retinoids (e.g. Accutane®)

          2. therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are
             allowed).

        Subjects who have used estrogens or oral contraceptives for less than 3 months prior to
        baseline; use of such therapy must remain constant throughout the study.

        Subjects who use androgen receptor blockers (such as spironolactone or flutamide) will be
        excluded from study participation.

        Subjects who have had cosmetic procedures (e.g., facials, wax depilation) which may affect
        the efficacy and safety profile of the investigational product within 14 days prior to
        study entry. Cosmetic procedures and facials are prohibited throughout the study.

        Subjects who have received radiation therapy and/or anti-neoplastic agents within 90 days
        prior to baseline.

        Subjects who have had laser therapy, electrodessication and phototherapy (e.g.,
        ClearLight®) to the facial area within 180 days prior to study entry.

        Subjects who have used any of the following procedures on the face within 1 month prior to
        baseline or during the study:

          1. cryodestruction or chemodestruction,

          2. dermabrasion,

          3. photodynamic therapy,

          4. acne surgery,

          5. intralesional steroids, or

          6. X-ray therapy.

        Subjects who have used any of the following treatments within 1 month prior to baseline or
        during the study:

          1. systemic corticosteroids (including intranasal and inhaled corticosteroids)

          2. systemic antibiotics,

          3. systemic treatment for acne vulgaris (other than oral retinoids which need a 6-month
             washout), or

          4. systemic anti-inflammatory agents.

        Subjects who have used any of the following treatments within 14 days prior to baseline or
        during the study:

          1. topical steroids,

          2. topical retinoids including over-the-counter preparations,

          3. α-hydroxy/glycolic acid

          4. topical anti-inflammatory agents, or

          5. topical antibiotics.

        Subjects who have started hormonal therapy or changed the dosage of their hormonal therapy
        within 3 months prior to baseline will be excluded from study participation. The dosage and
        frequency of use of any hormonal therapy started greater than 3 months prior to baseline
        must remain unchanged throughout the study (Visit 1 through Visit 4). Hormonal treatments
        include, but are not limited to, estrogenic and progestational agents such as birth control
        pills.

        Subjects who have unstable medical disorders that are clinically significant or
        life-threatening diseases will be excluded from study participation.

        Subjects with current facial sunburn at baseline or subjects who will have excessive use of
        tanning booths, sunbathing, or excessive exposure to the sun during the study.

        Subjects who will engage in activities that involve excessive or prolonged exposure to
        sunlight or weather extremes, such as wind or cold.

        Subjects who have on-going malignancies requiring systemic treatment will be excluded from
        study participation. In addition, Subjects who have any malignancy of the skin of the
        facial area will be excluded.

        Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use
        drugs of abuse (including, but not limited to cannabinoids, cocaine and barbiturates).

        Subjects who have had general anesthesia for any reason and subjects who have received
        neuromuscular blocking agents within 14 days prior to study entry will be excluded from
        study participation.

        Subjects who have participated in an investigational drug study (i.e., Subjects have been
        treated with an Investigational Drug) within 30 days prior to baseline will be excluded
        from study participation. Subjects who are participating in non-treatment studies such as
        observational studies or registry studies can be considered for inclusion.

        Subjects who have been previously enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keri Winkler</last_name>
    <role>Study Director</role>
    <affiliation>Akesis, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Miramar</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Research Collaborative</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM International</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belize</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>April 7, 2020</results_first_submitted>
  <results_first_submitted_qc>April 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2020</results_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>893 subjects were randomized and analyzed; 869 qualified for the mITT population and 758 for the PP population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test</title>
          <description>Tazarotene 0.1% foam (Actavis LLC)</description>
        </group>
        <group group_id="P2">
          <title>Reference</title>
          <description>Reference listed drug: Fabior™ 0.1% (tazarotene) foam (Stiefel Laboratories LLC)</description>
        </group>
        <group group_id="P3">
          <title>Vehicle</title>
          <description>Vehicle foam of the test product (Actavis LLC)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 874 (97.9%) of the 893 randomized subjects applied study treatment during the baseline visit, and were therefore retained in the Safety population.</population>
      <group_list>
        <group group_id="B1">
          <title>Test</title>
          <description>Tazarotene 0.1% foam (Actavis LLC)</description>
        </group>
        <group group_id="B2">
          <title>Reference</title>
          <description>Reference listed drug: Fabior™ 0.1% (tazarotene) foam (Stiefel Laboratories LLC)</description>
        </group>
        <group group_id="B3">
          <title>Vehicle</title>
          <description>Vehicle foam of the test product (Actavis LLC)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="292"/>
            <count group_id="B2" value="288"/>
            <count group_id="B3" value="294"/>
            <count group_id="B4" value="874"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="7.76"/>
                    <measurement group_id="B2" value="21.1" spread="7.26"/>
                    <measurement group_id="B3" value="21.0" spread="7.03"/>
                    <measurement group_id="B4" value="21.2" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="327"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="187"/>
                    <measurement group_id="B4" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="531"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="530"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts</title>
        <description>For the purposes of study treatment and evaluation, these lesions were limited to the facial treatment area excluding the eyes, the lips, and angles of the nose (i.e., the lines around the nostrils and under the nostrils) and all mucus membranes.</description>
        <time_frame>Mean percent change from baseline to Week 12</time_frame>
        <population>Mean percent change from baseline to Week 12 in Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene 0.1% foam (Actavis LLC)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>Reference listed drug: Fabior™ 0.1% (tazarotene) foam (Stiefel Laboratories LLC)</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Placebo foam (Actavis LLC)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts</title>
          <description>For the purposes of study treatment and evaluation, these lesions were limited to the facial treatment area excluding the eyes, the lips, and angles of the nose (i.e., the lines around the nostrils and under the nostrils) and all mucus membranes.</description>
          <population>Mean percent change from baseline to Week 12 in Per Protocol Population</population>
          <units>Percent change in inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.25" spread="26.743"/>
                    <measurement group_id="O2" value="-52.72" spread="22.792"/>
                    <measurement group_id="O3" value="-45.03" spread="24.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of mean percent change from baseline were calculated (separately for inflammatory and non-inflammatory lesions) for the Test and Reference treatment, and then the 90% confidence interval (CI) for the mean ratio was constructed using Fieller’s method.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Therapeutic equivalence was established if the 90% CIs for the ratio of Test/Reference means, for both lesion types, were contained within the interval [0.80, 1.25] for the PP population.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts</title>
        <description>Estimates of mean percent change from baseline for non-inflammatory lesions for the Test and Reference treatment.</description>
        <time_frame>Mean percent change from baseline to Week 12</time_frame>
        <population>Percent change in the non-inflammatory lesions in Per Protocol Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene 0.1% foam (Actavis LLC)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>Reference listed drug: Fabior™ 0.1% (tazarotene) foam (Stiefel Laboratories LLC)</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Foam</title>
            <description>Placebo Foam (Actavis LLC)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts</title>
          <description>Estimates of mean percent change from baseline for non-inflammatory lesions for the Test and Reference treatment.</description>
          <population>Percent change in the non-inflammatory lesions in Per Protocol Population.</population>
          <units>percent change in noninflammatory lesion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.98" spread="21.125"/>
                    <measurement group_id="O2" value="-44.51" spread="20.062"/>
                    <measurement group_id="O3" value="-37.42" spread="24.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Estimates of mean percent change from baseline were calculated (separately for inflammatory and non-inflammatory lesions) for the Test and Reference treatment, and then the 90% confidence interval (CI) for the mean ratio was constructed using Fieller’s method.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Therapeutic equivalence was established if the 90% CIs for the ratio of Test/Reference means, for both lesion types, were contained within the interval [0.80, 1.25] for the PP population.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects With an IGA Score That is at Least 2 Grades Less Than the Baseline Assessment</title>
        <time_frame>IGA score at Week 12 compared to baseline</time_frame>
        <population>Treatment success based on IGA score at Week 12 in PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene 0.1% foam (Actavis LLC)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>Reference listed drug: Fabior™ 0.1% (tazarotene) foam (Stiefel Laboratories LLC)</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Vehicle foam of the test product (Actavis LLC)</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects With an IGA Score That is at Least 2 Grades Less Than the Baseline Assessment</title>
          <population>Treatment success based on IGA score at Week 12 in PP population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Success was defined as an IGA score at Week 12 that was at least two grades less than the baseline assessment. Failure was defined as an IGA score that was the same, higher, or one grade lower than the baseline assessment.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Therapeutic equivalence was established if the 90% CI for the difference was contained within the interval [-0.20, +0.20] for PP population.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.073</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.150</ci_lower_limit>
            <ci_upper_limit>0.004</ci_upper_limit>
            <estimate_desc>Therapeutic equivalence was established if the 90% CI for the difference was contained within the interval [-0.20, +0.20] for the PP population.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over approximately 13 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Tazarotene 0.1% foam (Actavis LLC)</description>
        </group>
        <group group_id="E2">
          <title>Reference</title>
          <description>Reference listed drug: Fabior™ 0.1% (tazarotene) foam (Stiefel Laboratories LLC)</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>Vehicle foam of the test product (Actavis LLC)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Eye Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Localized infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedinfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

